Literature DB >> 15994270

Pulmonary hypertension in chronic obstructive pulmonary disease: current theories of pathogenesis and their implications for treatment.

J L Wright1, R D Levy, A Churg.   

Abstract

The development of pulmonary hypertension is a poor prognostic sign in patients with chronic obstructive pulmonary disease (COPD), affecting both mortality and quality of life. Although pulmonary hypertension in COPD is traditionally viewed as a result of emphysematous destruction of the vascular bed and/or hypoxia, recent studies indicate that neither of these factors correlates very well with pulmonary artery pressures. New human and animal experimental data are beginning to show that pulmonary hypertension in this setting is probably a result of the direct effect of tobacco smoke on the intrapulmonary vessels with abnormal production of mediators that control vasoconstriction, vasodilatation, and vascular cell proliferation, ultimately leading to aberrant vascular remodelling and aberrant vascular physiology. These changes are in many ways similar to those seen in other forms of pulmonary hypertension and suggest that the treatments used for primary pulmonary hypertension may be beneficial in patients with COPD.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15994270      PMCID: PMC1747459          DOI: 10.1136/thx.2005.042994

Source DB:  PubMed          Journal:  Thorax        ISSN: 0040-6376            Impact factor:   9.139


  35 in total

Review 1.  Pathobiology of pulmonary hypertension. Extracellular matrix.

Authors:  M Rabinovitch
Journal:  Clin Chest Med       Date:  2001-09       Impact factor: 2.878

2.  Vascular endothelial growth factor signals endothelial cell production of nitric oxide and prostacyclin through flk-1/KDR activation of c-Src.

Authors:  H He; V J Venema; X Gu; R C Venema; M B Marrero; R B Caldwell
Journal:  J Biol Chem       Date:  1999-08-27       Impact factor: 5.157

3.  Bosentan therapy for pulmonary arterial hypertension.

Authors:  Lewis J Rubin; David B Badesch; Robyn J Barst; Nazzareno Galie; Carol M Black; Anne Keogh; Tomas Pulido; Adaani Frost; Sebastien Roux; Isabelle Leconte; Michael Landzberg; Gerald Simonneau
Journal:  N Engl J Med       Date:  2002-03-21       Impact factor: 91.245

4.  Reduced hypoxic pulmonary vascular remodeling by nitric oxide from the endothelium.

Authors:  M Ozaki; S Kawashima; T Yamashita; Y Ohashi; Y Rikitake; N Inoue; K I Hirata; Y Hayashi; H Itoh; M Yokoyama
Journal:  Hypertension       Date:  2001-02       Impact factor: 10.190

Review 5.  Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: National Heart, Lung, and Blood Institute and World Health Organization Global Initiative for Chronic Obstructive Lung Disease (GOLD): executive summary.

Authors:  R A Pauwels; A S Buist; P Ma; C R Jenkins; S S Hurd
Journal:  Respir Care       Date:  2001-08       Impact factor: 2.258

6.  "Natural history" of pulmonary hypertension in a series of 131 patients with chronic obstructive lung disease.

Authors:  R Kessler; M Faller; E Weitzenblum; A Chaouat; A Aykut; A Ducoloné; M Ehrhart; M Oswald-Mammosser
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

7.  Prostacyclin receptor-dependent modulation of pulmonary vascular remodeling.

Authors:  Y Hoshikawa; N F Voelkel; T L Gesell; M D Moore; K G Morris; L A Alger; S Narumiya; M W Geraci
Journal:  Am J Respir Crit Care Med       Date:  2001-07-15       Impact factor: 21.405

8.  Pulmonary artery remodeling modifies pulmonary hypertension during exercise in severe emphysema.

Authors:  K Kubo; R L Ge; T Koizumi; K Fujimoto; T Yamanda; M Haniuda; T Honda
Journal:  Respir Physiol       Date:  2000-03

9.  Sputum and plasma endothelin-1 levels in exacerbations of chronic obstructive pulmonary disease.

Authors:  M Roland; A Bhowmik; R J Sapsford; T A Seemungal; D J Jeffries; T D Warner; J A Wedzicha
Journal:  Thorax       Date:  2001-01       Impact factor: 9.139

10.  Nitric oxide gas decreases endothelin-1 mRNA in cultured pulmonary artery endothelial cells.

Authors:  Adrian P L Smith; Eric A G Demoncheaux; Tim W Higenbottam
Journal:  Nitric Oxide       Date:  2002-03       Impact factor: 4.427

View more
  47 in total

1.  Transdifferentiation of pulmonary arteriolar endothelial cells into smooth muscle-like cells regulated by myocardin involved in hypoxia-induced pulmonary vascular remodelling.

Authors:  Pengcheng Zhu; Lei Huang; Xiaona Ge; Fei Yan; Renliang Wu; Qilin Ao
Journal:  Int J Exp Pathol       Date:  2006-12       Impact factor: 1.925

2.  IL-18 induces emphysema and airway and vascular remodeling via IFN-γ, IL-17A, and IL-13.

Authors:  Min-Jong Kang; Je-Min Choi; Bo Hye Kim; Chang-Min Lee; Won-Kyung Cho; Gina Choe; Do-Hyun Kim; Chun Geun Lee; Jack A Elias
Journal:  Am J Respir Crit Care Med       Date:  2012-03-01       Impact factor: 21.405

3.  MicroRNA-338-5p modulates pulmonary hypertension-like injuries caused by SO2, NO2 and PM2.5 co-exposure through targeting the HIF-1α/Fhl-1 pathway.

Authors:  Xiaotong Ji; Yingying Zhang; Tingting Ku; Yang Yun; Guangke Li; Nan Sang
Journal:  Toxicol Res (Camb)       Date:  2016-09-09       Impact factor: 3.524

Review 4.  Pulmonary hypertension survival effects and treatment options in cystic fibrosis.

Authors:  Adriano R Tonelli
Journal:  Curr Opin Pulm Med       Date:  2013-11       Impact factor: 3.155

Review 5.  Animal models of chronic obstructive pulmonary disease.

Authors:  Joanne L Wright; Manuel Cosio; Andrew Churg
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2008-05-02       Impact factor: 5.464

6.  Role of chymase in cigarette smoke-induced pulmonary artery remodeling and pulmonary hypertension in hamsters.

Authors:  Tao Wang; Su-Xia Han; Shang-Fu Zhang; Yun-Ye Ning; Lei Chen; Ya-Juan Chen; Guang-Ming He; Dan Xu; Jin An; Ting Yang; Xiao-Hong Zhang; Fu-Qiang Wen
Journal:  Respir Res       Date:  2010-03-31

7.  Plasma C-reactive protein and endothelin-1 level in patients with chronic obstructive pulmonary disease and pulmonary hypertension.

Authors:  Yong Soo Kwon; Su Young Chi; Hong Joon Shin; Eun Young Kim; Byeong Kab Yoon; Hee Jung Ban; In Jae Oh; Kyu Sik Kim; Young Chul Kim; Sung Chul Lim
Journal:  J Korean Med Sci       Date:  2010-09-17       Impact factor: 2.153

8.  ERK1/2 promotes cigarette smoke-induced rat pulmonary artery smooth muscle cells proliferation and pulmonary vascular remodeling via up-regulating cycline1 expression.

Authors:  Mu-Qing Yu; Xian-Sheng Liu; Hong-Xu Wu; Min Xiang; Yong-Jian Xu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2013-06-17

Review 9.  Association of chronic obstructive pulmonary disease and obstructive sleep apnea consequences.

Authors:  Carlos Zamarrón; Vanesa García Paz; Emilio Morete; Felix del Campo Matías
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2008

Review 10.  Targeted treatment in COPD: a multi-system approach for a multi-system disease.

Authors:  David Anderson; William Macnee
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2009-09-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.